Table 4 The treatments and outcomes of IIM patients according to the levels of hs-cTnI.
Total (n = 142) | hs-cTnI < 30pg/mL (n = 105) | hs-cTnI > 30pg/mL (n = 37) | p - values | |
|---|---|---|---|---|
Treatments | ||||
Highest methyprednisolone dose (mg/day), median (IQR) | 50.0 (40.0–80.0) | 40.0 (20.0–80.0) | 80.0 (80.0–80.0) | < 0.001 |
Application of MTX, n (%) | 7 (4.9) | 6 (5.7) | 1 (2.7) | 0.467 |
Application of CTX, n (%) | 10 (7.0) | 7 (6.7) | 3 (8.1) | 0.768 |
Application of IVIG, n (%) | 23 (16.2) | 14 (13.3) | 9 (24.3) | 0.119 |
Application of biologic agents, n (%) | 6 (4.2) | 1 (2.7) | 5 (4.8) | 0.592 |
Application of PE, n (%) | 5 (3.5) | 3 (2.9) | 2 (5.4) | 0.470 |
Application of beta blocker and ACE inhibitor/ARB, n (%) | 18 (12.7) | 8 (7.6) | 10 (27.0) | 0.002 |
Application of statin, n (%) | 3 (2.1) | 2 (1.9) | 1 (2.7) | 0.772 |
Application of antiplatelet/anticoagulant treatment, n (%) | 14 (9.9) | 4 (3.8) | 10 (27.0) | < 0.001 |
Outcomes | ||||
Death, n (%) | 3 (2.1) | 0 (0.0) | 3 (8.1) | 0.004 |